Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
43.2M
-
Shares change
-
+2.56M
-
Total reported value, excl. options
-
$2B
-
Value change
-
+$107M
-
Put/Call ratio
-
1.57
-
Number of buys
-
78
-
Number of sells
-
-65
-
Price
-
$46.38
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2017
185 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2017.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.2M shares
of 96M outstanding shares and own 45.04% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (5.86M shares), Capital Research Global Investors (4.99M shares), BlackRock Inc. (3.73M shares), FMR LLC (3.64M shares), Capital International Investors (3.58M shares), Vanguard Group Inc (3.17M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.12M shares), STATE STREET CORP (1.6M shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (1.44M shares), and FEDERATED INVESTORS INC /PA/ (1.1M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.